CRESSKILL, N.J., Nov. 4, 2021 /PRNewswire/ -- Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today, the company announced the presentation of clinical results from its Phase 3 clinical trial (ACCESS 1) during the Late Breaking Clinical Trials section of the American Association of Nephrology Annual Meeting. The results were presented by Maria DeVita, MD, Senior Nephrologist at Lenox Hill Hospital in New York and Medical Monitor for the study.